[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355802-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355802-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-novel-colchicine-binding-site-inhibitor-suppresses-triple-negative-breast-cancer-growth-and-metastasis-and-synergizes-with-anti-pd-l1-immunotherapy-in-an-immunogenic-cancer-model","A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model","","Triple-negative breast cancer (TNBC) comprises about 15% of breast cancer cases and lacks estrogen receptor, progesterone receptor, and HER2 expression. Nearly 40% of patients develop metastasis, with median survival around 13.3 months, and current chemotherapy such as paclitaxel is limited by ATP-driven drug efflux and related resistance. A colchicine-binding site inhibitor designed to target tubulin can induce G2/M arrest and apoptosis and may bypass taxane resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-novel-colchicine-binding-site-inhibitor-suppresses-triple-negative-breast-cancer-growth-and-metastasis-and-synergizes-with-anti-pd-l1-immunotherapy-in-an-immunogenic-cancer-model/355802/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-novel-colchicine-binding-site-inhibitor-suppresses-triple-negative-breast-cancer-growth-and-metastasis-and-synergizes-with-anti-pd-l1-immunotherapy-in-an-immunogenic-cancer-model/355802.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What defines triple-negative breast cancer (TNBC)?","Question",{"text":63,"@type":64},"TNBC is defined by absent estrogen receptor, progesterone receptor, and HER2 expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is paclitaxel efficacy often limited in TNBC?",{"text":68,"@type":64},"Efficacy is often constrained by ATP-driven efflux and mechanisms that contribute to chemoresistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the document propose synergy with immunotherapy?",{"text":72,"@type":64},"The described CBSI increases PD-L1 expression, supporting combination with anti-PD-L1 immune checkpoint inhibition.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355802,1790194487,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Biomed Pharmacother. Author manuscript; available in PMC 2026 June 01. |\n| --- | --- |\n\nPublished in final edited form as:  \nBiomed Pharmacother. 2026 May ; 198: 119353. doi:10.1016/j.biopha.2026.119353 .  \nA novel colchicine-binding site inhibitor suppresses triplenegative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model  \nKelli L. Adeleyea, Damilola Oluwalanab,c, Raisa Krutilinac,d, Yang Xiea, Satyanarayana Pochampallya, Lily Waltza, Gustavo A. Miranda-Carbonie, Duane D. Millera, Tiffany N. Seagrovesc,d, Wei Lia,*  \na Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States  \nb Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN 38105, United States  \nc Department of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States  \nd John W. Deming Department of Medicine and Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, LA 70112, United States  \ne Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States  \nAbstract  \nTriple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression. Approximately 40% of patients with TNBC develop metastatic disease, reducing median survival to 13.3 months. Paclitaxel remains a standard chemotherapeutic option; however, its efficacy is often limited by ATP-driven efflux  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Correspondence to: The University of Tennessee Health Science Center, College of Pharmacy, Department of Pharmaceutical Sciences, 881 Madison Avenue, Room 561, Memphis, TN 38163, [United States. wli@uthsc.edu](United States. wli@uthsc.edu) (W. Li).  \nDeclaration of Competing Interest  \nDrs. Wei Li and Duane Miller are inventors listed on a US patent covering SB-216 and SP-1–39 . Dr. Wei Li is a scientific consultant for Veru, Inc., and is the founder of SEAK Therapeutics, LLC. However, neither Veru Inc. or SEAK Therapeutics LLC has any influence on the design, data collection, or data interpretation in this study. None of the other authors has any other disclosures. CRediT authorship contribution statement  \nSatyanarayana Pochampally: Writing – review & editing, Resources. Gustavo A. Miranda-Carboni: Writing – review & editing, Validation, Resources, Investigation. Raisa Krutilina: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Data curation. Yang Xie: Writing – review & editing, Writing – original draft, Investigation. Kelli L. Adeleye: Writing – review & editing, Writing – original draft, Validation, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Damilola Oluwalana: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Data curation. Lily Waltz: Investigation, Writing – review & editing. Wei Li: Writing – review & editing, Writing – original draft, Supervision, Resources, Project administration, Methodology, Conceptualization. Duane D. Miller: Writing – review & editing, Resources, Conceptualization.  \nTiffany N. Seagroves: Writing – review & editing, Writing – original draft, Resources.  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nAdeleye et al. Page 2  \npumps and βIII-tubulin overexpression. These limitations underscore the need for agents that can overcome resistance and suppress metastasis. Colchici","cbCaibqIgV36lpkr","https://ap.wps.com/l/cbCaibqIgV36lpkr","pdf",3791852,34,"English","# Abstract\n## Background and clinical challenge\n## Rationale for colchicine-binding site inhibition\n## Study aim and therapeutic combination","[{\"question\":\"What defines triple-negative breast cancer (TNBC)?\",\"answer\":\"TNBC is defined by absent estrogen receptor, progesterone receptor, and HER2 expression.\"},{\"question\":\"Why is paclitaxel efficacy often limited in TNBC?\",\"answer\":\"Efficacy is often constrained by ATP-driven efflux and mechanisms that contribute to chemoresistance.\"},{\"question\":\"How does the document propose synergy with immunotherapy?\",\"answer\":\"The described CBSI increases PD-L1 expression, supporting combination with anti-PD-L1 immune checkpoint inhibition.\"}]","A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model | PDF",1790121071,86,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02664af125341d9722d21cacf5b49074.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cd78d6937dbeff657e5a64a75965068.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2fd6a1750648327be21239ac8688cc0.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3021421c033952a0660ea7a8866947c2.webp",980,1268]